Immunomodulatory Effects of Novel Therapies for Stroke
Each year, approximately 795,000 people suffer a new or recurrent stroke. About 610,000 of these are first attacks, and 185,000 are recurrent attacks (Carandang et al. 2006). Currently the only FDA approved treatment for ischemic stroke is recombinant tissue plasminogen activator (Alteplase) (Marler...
| Main Author: | |
|---|---|
| Format: | Others |
| Published: |
Scholar Commons
2009
|
| Subjects: | |
| Online Access: | https://scholarcommons.usf.edu/etd/1997 https://scholarcommons.usf.edu/cgi/viewcontent.cgi?article=2996&context=etd |